Objective: We aimed to investigate in-situ expression of interleukin IL-17A, IL-21, IL-22, and IL-35 in lupus nephritis (LN).
Methods: A cross-sectional study using immunohistochemistry (IHC) in renal biopsy to detect in-situ expression of interleukin IL-17 family and IL-35 from 20 Mexican patients with moderate to severe LN.
Results: We found predominant expression of IL-17A and IL-21 in the glomerular region. IL-22 was detected in the tubulointerstitium and inflammatory aggregates, notwithstanding IL-21 and IL-35 in fibrotic and atrophic tubules. A positive correlation was found between IL-17A expression in the glomerulus and tubulointerstitium with creatinine, urea, and blood urea nitrogen levels, whereas IL-35 expression decreases in the presence of proteinuria. IL-21 was high in disease activity and severity versus IL-35 that decreased in systemic lupus erythematosus (SLE) disease activity.
Conclusions: These findings provide evidence for the compartment-specific expression in LN of Th17-related cytokines and IL-35 in Mexican patients.
PergeBPappGBóiB, et al.Clinical features and survival analysis of lupus nephritis among patients with systemic lupus erythematosus: a three-decade-long retrospective cohort study. Biomedicines; 12: 2117. DOI: 10.3390/biomedicines12092117, Epub ahead of print 18 September 2024.
2.
Aguilera Barragán-PickensGHerrera van-OostdamDIrazoque-PalazuelosF, et al. Lupus nephritis in Mexican patients: response to intensive therapy. Reumatol Clin (Engl Ed). 2025. doi:10.1016/j.reumae.2025.501896.
3.
SiegelCHSammaritanoLR. Systemic lupus erythematosus: a review. JAMA2024; 331: 1480–1491.
4.
AndersH-JSaxenaRZhaoM, et al.Lupus nephritis. Nat Rev Dis Primers2020; 6: 7.
5.
YapDYHChanTM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis—role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci2019; 20: 6231.
6.
ChoiJ-YSethAKashgarianM, et al.Disruption of pathogenic cellular networks by IL-21 blockade leads to disease amelioration in Murine lupus. J Immunol2017; 198: 2578–2588.
7.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019; 78: 1151–1159.
8.
PetriMKimMYKalunianKC, et al.Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558.
9.
RovetaAParodiELBrezziB, et al.Lupus nephritis from pathogenesis to new therapies: an update. Int J Mol Sci2024; 25: 8981.
10.
MillsKHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol2023; 23: 38–54.
11.
NiedbalaWWeiXCaiB, et al.IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol2007; 37: 3021–3029.
12.
CollisonLWWorkmanCJKuoTT, et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature2007; 450: 566–569.
13.
PetrićMRadićM. Is Th17-Targeted therapy effective in systemic lupus erythematosus?Curr Issues Mol Biol2023; 45: 4331–4343.
14.
McGeachyMJCuaDJGaffenSL. The IL-17 family of cytokines in health and disease. Immunity2019; 50: 892–906.
15.
LiuSMKingC. IL-21–Producing Th cells in immunity and autoimmunity. J Immunol2013; 191: 3501–3506.
16.
KohC-HKimB-SKangC-Y, et al.IL-17 and IL-21: their immunobiology and therapeutic potentials. Immune Netw2024; 24: e2. DOI: 10.4110/in.2024.24.e2, Epub ahead of print 2024.
17.
InoueTKurosakiT. Memory B cells. Nat Rev Immunol2024; 24: 5–17.
18.
QuastIDvorscekARPattaroniC, et al.Interleukin-21, acting beyond the immunological synapse, independently controls T follicular helper and germinal center B cells. Immunity2022; 55: 1414–1430.e5.
19.
WeiLLaurenceAEliasKM, et al.IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem2007; 282: 34605–34610.
20.
ChenQYangWGuptaS, et al.IRF-4-Binding protein inhibits Interleukin-17 and Interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity2008; 29: 899–911.
21.
YaziciMUOrhanDKaleG, et al.Studying IFN-gamma, IL-17 and FOXP3 in pediatric lupus nephritis. Pediatr Nephrol2014; 29: 853–862.
22.
PaquissiFCAbensurH. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med2021; 8: 654912. DOI: 10.3389/fmed.2021.654912, Epub ahead of print 3 September 2021.
23.
OhlKTenbrockK. Inflammatory cytokines in systemic lupus erythematosus. BioMed Res Int2011; 2011: 432595. DOI: 10.1155/2011/432595, Epub ahead of print 16 January 2011.
24.
AmarilyoGLourençoEVShiF-D, et al.IL-17 promotes Murine lupus. J Immunol2014; 193: 540–543.
25.
DolffSAbdulahadWHWestraJ, et al.Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther2011; 13: R157.
26.
ZickertAAmoudruzPSundströmY, et al.IL-17 and IL-23 in lupus nephritis - Association to histopathology and response to treatment. BMC Immunol2015; 16: 7.
27.
ChenD-YChenY-MWenM-C, et al.The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus2012; 21: 1385–1396.
28.
WangYItoSChinoY, et al.Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol2009; 159: 1–10.
29.
CrispínJCOukkaMBaylissG, et al.Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol2008; 181: 8761–8766.
30.
KimJMJeongHJKimSH, et al.AB0139 interleukin-21 is overexpressed in kidney tissue from lupus nephritis patients and its serum levels are correlated with systemic lupus erythematosus disease activity. Ann Rheum Dis2016; 75: 944.
31.
PaustH-JTurnerJ-ESteinmetzOM, et al.The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol2009; 20: 969–979.
32.
HerberDBrownTPLiangS, et al.IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol2007; 178: 3822–3830.
33.
YeCYanoHWorkmanCJ, et al.Interleukin-35: structure, function and its impact on immune-related diseases. J Interferon Cytokine Res2021; 41: 391–406.
34.
MaQLuanJBaiY, et al.Interleukin-22 in renal protection and its pathological role in kidney diseases. Front Immunol2022; 13: 851818. DOI: 10.3389/fimmu.2022.851818, Epub ahead of print 31.
35.
LiJWuZWuY, et al.IL-22, a vital cytokine in autoimmune diseases. Clin Exp Immunol2024; 218: 242–263.
36.
JiangQYangGXiaoF, et al.Role of Th22 cells in the pathogenesis of autoimmune diseases. Front Immunol2024; 12: 688066. DOI: 10.3389/fimmu.2021.688066, Epub ahead of print 6 July 2021.
